{"entity":{"id":"cero-therapeutics","kind":"company","name":"CERo Therapeutics","aka":["CERo Therapeutics Holdings, Inc."],"tldr":"CERo Therapeutics engineers a patient's own T cells so that they can both kill cancer cells and swallow their fragments, a job normally done by other immune cells. Its first product, CER-1236, is in an early trial in acute myeloid leukaemia and related bone marrow cancers.","summary":"CERo Therapeutics Holdings, Inc., based at 201 Haskins Way, South San Francisco, California, develops chimeric engulfment receptor T (CER-T) cells, autologous T cells engineered to combine cytotoxic killing with phagocytosis and antigen presentation. Its lead product CER-1236 targets TIM-4 ligand (phosphatidylserine), an 'eat me' signal exposed on stressed and abnormal cells. The FDA cleared the IND in November 2024 after a brief clinical hold, and a phase 1 study in AML, myelodysplastic syndrome and myelofibrosis is registered (NCT06834282); the company has filed a second IND for non-small cell lung cancer and ovarian cancer. The predecessor, CERo Therapeutics, Inc., was incorporated in Delaware on 23 September 2016 and went public by business combination with Phoenix Biotech Acquisition Corp. in February 2024; Nasdaq suspended trading in October 2025, the shares moved to the OTCQB in December 2025, and the delisting was affirmed in January 2026, according to the company's annual report. Its first registered cancer trial, NCT06834282, was posted on ClinicalTrials.gov in February 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://cero.bio/"},{"label":"Form 10-K, filed 15 April 2026","url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm"},{"label":"ClinicalTrials.gov: phase 1 trial of CER-1236 in AML, MDS and myelofibrosis (NCT06834282)","url":"https://clinicaltrials.gov/study/NCT06834282"}],"tags":[],"related":[],"cancers":["aml","mds","primary-myelofibrosis"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: cero.bio about, pipeline and news pages, and the Form 10-K filed on 15 April 2026 (SEC CIK 0001870404). The founding year is the predecessor's incorporation date given in that filing.","The company pipeline page still showed CER-1236 as IND-enabling when read, which is out of date relative to the registry record. No target record for TIM-4 ligand exists in OnCo.","Trial facts from the ClinicalTrials.gov record NCT06834282, read on 29 October 2026."],"hq":"South San Francisco, CA","country":"US","companyType":"cell-therapy","website":"https://cero.bio/","ticker":"CERO","founded":2016,"stage":"public","investors":[],"funding":[]},"route":"/companies/cero-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}]}}